How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eptinezumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vyepti — Competitive Intelligence Brief

Vyepti (EPTINEZUMAB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcitonin Gene-related Peptide Antagonist [EPC]. Area: Neuroscience.

marketed Calcitonin Gene-related Peptide Antagonist [EPC] Calcitonin gene-related peptide 1 Neuroscience Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Vyepti (EPTINEZUMAB) — Lundbeck Seattle BioPharmaceuticals, Inc.. Vyepti works by blocking the action of calcitonin gene-related peptide 1, a molecule involved in migraine pain.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyepti TARGET	EPTINEZUMAB	Lundbeck Seattle BioPharmaceuticals, Inc.	marketed	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1	2020-01-01
Ajovy	FREMANEZUMAB	Teva	marketed		Calcitonin gene-related peptide 1	2018-01-01
Emgality	GALCANEZUMAB	Eli Lilly	marketed		Calcitonin gene-related peptide 1	2018-01-01
VYEPTI	EPTINEZUMAB-JJMR	Lundbeck Seattle BioPharmaceuticals, Inc.	marketed	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcitonin Gene-related Peptide Antagonist [EPC] class)

Lundbeck Seattle BioPharmaceuticals, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyepti — Competitive Intelligence Brief. https://druglandscape.com/ci/eptinezumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab